3-(2-methoxynaphthalen-1-yl)propanal | 878662-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(2-methoxynaphthalen-1-yl)propanal
• 英文别名: ethyl 3-(2'-methoxy-1'-naphthyl)propanal；3-(2'-methoxy-1'-naphthyl) propanal；3-(2-Methoxynaphthalen-1-yl)propanal
• CAS: 878662-31-8
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: IDQQHPAMACUHNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-methoxynaphthalen-1-yl)propanal 在 5%-palladium/activated carbon 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 C₁₈H₂₂O₃
  参考文献：
  名称：

  Evaluation of synthetic naphthalene derivatives as novel chemical chaperones that mimic 4-phenylbutyric acid

  摘要：

  The chemical chaperone 4-phenylbutyric acid (4-PBA) has potential as an agent for the treatment of neurodegenerative diseases. However, the requirement of high concentrations warrants chemical optimization for clinical use. In this study, novel naphthalene derivatives with a greater chemical chaperone activity than 4-PBA were synthesized with analogy to the benzene ring. All novel compounds showed chemical chaperone activity, and 2 and 5 possessed high activity. In subsequent experiments, the protective effects of the compounds were examined in Parkinson's disease model cells, and low toxicity of 9 and 11 was related to amphiphilic substitution with naphthalene. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.080
• 作为产物：
  描述：

  3-(2-methoxynaphthalen-1-yl)propan-1-ol 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 生成 3-(2-methoxynaphthalen-1-yl)propanal
  参考文献：
  名称：

  Evaluation of synthetic naphthalene derivatives as novel chemical chaperones that mimic 4-phenylbutyric acid

  摘要：

  The chemical chaperone 4-phenylbutyric acid (4-PBA) has potential as an agent for the treatment of neurodegenerative diseases. However, the requirement of high concentrations warrants chemical optimization for clinical use. In this study, novel naphthalene derivatives with a greater chemical chaperone activity than 4-PBA were synthesized with analogy to the benzene ring. All novel compounds showed chemical chaperone activity, and 2 and 5 possessed high activity. In subsequent experiments, the protective effects of the compounds were examined in Parkinson's disease model cells, and low toxicity of 9 and 11 was related to amphiphilic substitution with naphthalene. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.080

文献信息

• Synthesis of Spiroisoxazolines via an Oximation/Dearomatization Cascade under Air
  作者：Dengfeng Chen、Tianyu He、Yuan Huang、Jinyue Luo、Fei Wang、Shenlin Huang

  DOI：10.1021/acs.orglett.0c01429

  日期：2020.6.5

  transition-metal-free synthesis of spiroisoxazolines is outlined. This protocol provides, for the first time, a direct access to spiroisoxazolines from aryl (thio)ethers or (thio)phenols in one synthetic step via an oximation/dearomatization cascade. In this reaction, sodium nitrite plays dual roles: as a hydroxylamine source and also a precatalyst to promote the aerobic dearomatization. This methodology features

  概述了螺异恶唑啉的无过渡金属催化合成。该方案首次在一个合成步骤中通过肟化/脱芳香化反应的级联，直接从芳基（硫）醚或（硫）酚中获得螺异恶唑啉。在该反应中，亚硝酸钠起着双重作用：既是羟胺源，又是促进有氧脱芳香化作用的前催化剂。这种方法具有前所未有的底物范围，高收率，可扩展性，可持续的氧化剂和温和的条件。
• 5-HT2B receptor antagonists
  申请人：——

  公开号：US20040010022A1

  公开（公告）日：2004-01-15

  The present invention relates to compounds of formula I: 1 wherein one of R 1 and R 4 is selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl, and phenyl-C 1-4 alkyl; and the other of R 1 and R 4 is an optionally substituted C 9-14 aryl group; R 2 and R 3 are either: (i) independently selected from H, R, R′, SO 2 R, C(═O)R, (CH 2 ) n NR 5 R 6 , where n is from 1 to 4 and R 5 and R 6 are independently selected from H and R, where R is optionally substituted C 1-4 alkyl, and R′ is optionally substituted phenyl-C 1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C 5-7 heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT 2B receptor.

  本发明涉及公式I的化合物： 1 其中R 1 和R 4 之一选自由H、以及可选地取代的C 1-6 烷基、C 3-7 环烷基、C 3-7 环烷基-C 1-4 烷基和苯基-C 1-4 烷基组成的组；R 1 和R 4 的另一个是可选地取代的C 9-14 芳基基团；R 2 和R 3 是： (i)独立地选自H、R、R′、SO 2 R、C(═O)R、(CH 2 ) n NR 5 R 6 ，其中n是从1到4，R 5 和R 6 独立地选自H和R，其中R是可选地取代的C 1-4 烷基，R′是可选地取代的苯基-C 1-4 烷基，或 (ii)与它们连接的氮原子一起，形成一个可选地取代的C 5-7 杂环基团；以及它们作为药物的使用，特别用于治疗通过5-HT 2B 受体的拮抗作用减轻的状况。
• [EN] 5-HT2B RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR 5-HT2B
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005012263A1

  公开（公告）日：2005-02-10

  Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor.

  化合物的分子式：（I）、（II）、（IIIa）、（IIIb）、（IVa）和（IVb）：或其药用可接受的盐，用作药物，特别用于治疗通过拮抗5-HT2B受体缓解的病症。
• 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors
  作者：Troy Voelker、Haiji Xia、Keith Fandrick、Robert Johnson、Aaron Janowsky、John R. Cashman

  DOI：10.1016/j.bmc.2009.01.023

  日期：2009.3

  were prepared based on (−)-cocaine and aryltropanes as lead compounds because they are reasonably potent 5-HT re-uptake inhibitors. Molecular dissection of an aryltropane provided a series of 5- and 6-membered ring compounds. From among this library of compounds a series of disubstituted tetrahydrofurans bearing 2-alkyl aryl and 5-alkyl amino groups were identified as having highly potent and selective

  5-羟色胺（5-HT，5-羟色胺）神经传递的增强是治疗抑郁症的可行方法。基于该观察结果，基于（-）-可卡因和芳基环烷类作为先导化合物，制备了抑制5-HT再摄取的药物，因为它们是有效的5-HT再摄取抑制剂。芳基托烷的分子分解提供了一系列的5元和6元环化合物。从该化合物库中，鉴定出一系列带有2-烷基芳基和5-烷基氨基的二取代四氢呋喃具有高度有效和选择性的5-HT再摄取抑制作用。评价化合物与放射性标记的RTI-55结合竞争的能力以及在人多巴胺，5-羟色胺和去甲肾上腺素转运蛋白上抑制神经递质再摄取的能力。基于效力（例如，K i  = 800 pM）和显着的功能选择性（例如，人多巴胺：5-羟色胺或去甲肾上腺素：5-羟色胺的IC 50比，⩾1397）被确定为高效和选择性的5-羟色胺再摄取抑制剂。在结合亲和力和再摄取抑制中起主要作用的最佳特征包括芳族部分上的亲脂取代，反式2,5-二取代的四氢呋喃环的相对
• Modulators of Central Nervous System Neurotransmitters
  申请人：Cashman John

  公开号：US20080261967A1

  公开（公告）日：2008-10-23

  Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.

  本发明涉及具有药理活性的药物，特别是针对细胞受体和细胞内信号传导的药物，尤其是中枢神经系统（CNS）神经递质的受体和信号通路。本发明还涉及使用这些药物的相关方法和组合物，用于治疗或预防疾病或障碍。